Recovery and biodistribution of Ex vivo expanded human erythroblasts injected into NOD/SCID/IL2Rγ null mice

Anna Rita Migliaccio, Barbara Ghinassi, Leda Ferro, Francesca Masiello, Valentina Tirelli, Massimo Sanchez, Giovanni Migliaccio, Carolyn Whitsett, Stefan Kachala, Isabelle Riviere, Michel Sadelain

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Ex vivo expanded erythroblasts (EBs) may serve as advanced transfusion products provided that lodgment occurs in the macrophage-niche of the marrow permitting maturation. EBs expanded from adult and cord blood expressed the receptors (CXCR4, VLA-4, and P-selectin ligand 1) necessary for interaction with macrophages. However, 4-days following transfusion to intact NOD/SCID/IL2R null mice, CD 235 a p o s EBs were observed inside CD 235 a n e g splenic cells suggesting that they underwent phagocytosis. When splenectomized and intact NOD/SCID/IL2R null mice were transfused using retrovirally labeled human EBs, human cells were visualized by bioluminescence imaging only in splenectomized animals. Four days after injection, human CD 235 a p o s cells were detected in marrow and liver of splenectomized mice but only in spleen of controls. Human CD 235 a p o s erythrocytes in blood remained low in all cases. These studies establish splenectomized NOD/SCID/IL2R null mice as a suitable model for tracking and quantification of human EBs in vivo.

Original languageEnglish
Article number673752
JournalStem Cells International
DOIs
StatePublished - 2011

Fingerprint

Dive into the research topics of 'Recovery and biodistribution of Ex vivo expanded human erythroblasts injected into NOD/SCID/IL2Rγ null mice'. Together they form a unique fingerprint.

Cite this